These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population. Abelson MB; Ferzola NJ; McWhirter CL; Crampton HJ Pediatr Allergy Immunol; 2004 Dec; 15(6):551-7. PubMed ID: 15610370 [TBL] [Abstract][Full Text] [Related]
25. The anti-allergic effects of a cromolyn sodium-chlorpheniramine combination compared to ketotifen in the conjunctival allergen challenge model. Leonardi A; Busca F; Tavolato M; Secchi AG Eur J Ophthalmol; 2003 Mar; 13(2):128-33. PubMed ID: 12696630 [TBL] [Abstract][Full Text] [Related]
26. Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity. Heitner SB; Minnier J; Naher A; Van Woerkom RC; Ritts A; Ferencik M; Broberg C; Medvedova E; Silbermann R; Scott EC Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):796-802. PubMed ID: 30217616 [TBL] [Abstract][Full Text] [Related]
27. An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma. Hansen VL; Coleman M; Elkins S; Letzer JP; Levy MY; Seneviratne L; Rine J; White M; Kuriakose ET Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):400-407.e1. PubMed ID: 29656050 [TBL] [Abstract][Full Text] [Related]
28. Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma. Chee A; Low MS; Vilcassim S; Gregory GP; Gilbertson M; Ratnasingam S; Grigoriadis G; Fedele PL Br J Haematol; 2018 Sep; 182(5):739-741. PubMed ID: 28857117 [No Abstract] [Full Text] [Related]
29. Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients. Wu S; Zheng C; Chen S; Cai X; Shi Y; Lin B; Chen Y Biomed Res Int; 2015; 2015():927105. PubMed ID: 26425561 [TBL] [Abstract][Full Text] [Related]
30. Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse. Reyal Y; Popat R; Cheesman S; Rismani A; D'Sa S; Rabin N; Yong K Br J Haematol; 2017 May; 177(3):495-497. PubMed ID: 27062387 [No Abstract] [Full Text] [Related]
32. Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort. Grelaud A; Fourrier-Réglat A; Fitoussi O; Facon T; Jové J; Bénichou J; Robinson P; Marit G; Rouyer M; Moore N; Noize P; Leuk Lymphoma; 2016; 57(6):1349-54. PubMed ID: 26397802 [TBL] [Abstract][Full Text] [Related]
33. Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). Tessenow H; Holzvogt M; Holzvogt B; Andrea M; Heyn S; Schliwa T; Schwarz M; Zehrfeld T; Becker C; Pfrepper C; Franke GN; Krahl R; Jentzsch M; Leiblein S; Schwind S; Bill M; Vucinic V; Lange T; Niederwieser D; Pönisch W J Cancer Res Clin Oncol; 2017 Oct; 143(10):2049-2058. PubMed ID: 28534173 [TBL] [Abstract][Full Text] [Related]
34. Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis. Kam KW; Chen LJ; Wat N; Young AL Ocul Immunol Inflamm; 2017 Oct; 25(5):663-677. PubMed ID: 27192186 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332 [TBL] [Abstract][Full Text] [Related]
36. [Retrospective study comparing low-dose versus standard dose of bortezomib in patients with multiple myeloma]. Espinoza Zelada M; Befferman Cordova N; Ocqueteau Tachini M; Ramírez Villanueva P; Galleguillos M M; Sarmiento Maldonado M Medwave; 2015 Mar; 15(2):e6098. PubMed ID: 25831273 [TBL] [Abstract][Full Text] [Related]
37. Diffuse parenchymal pulmonary amyloidosis showing an objective response to bortezomib-based chemotherapy. Higo H; Fujiwara K; Watanabe H; Makimoto G; Kameyama N; Matsushita M; Rai K; Sato K; Inomata T; Sunami K; Shibayama T Intern Med; 2014; 53(16):1809-12. PubMed ID: 25130116 [TBL] [Abstract][Full Text] [Related]
38. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. Tuchman SA; Moore JO; DeCastro CD; Li Z; Sellars E; Kang Y; Long G; Gasparetto CG J Geriatr Oncol; 2017 May; 8(3):165-169. PubMed ID: 28256432 [TBL] [Abstract][Full Text] [Related]
39. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597 [TBL] [Abstract][Full Text] [Related]
40. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma. Nishihori T; Baz R; Shain K; Kim J; Ochoa-Bayona JL; Yue B; Sullivan D; Dalton W; Alsina M Eur J Haematol; 2015 Nov; 95(5):426-35. PubMed ID: 25600676 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]